SOURCE: HealthSonix Inc.

October 25, 2006 07:50 ET

HealthSonix Completes Its Second International Distribution Agreement for the enSonix@home Medical Device

IRVINE, CA -- (MARKET WIRE) -- October 25, 2006 -- HealthSonix, Inc. (PINKSHEETS: HSXI) (FRANKFURT: H7S) today announced that it has finalized a Letter of Intent with LINEA COMERCIAL LTDA. of Sao Paulo, Brazil to be the company's exclusive distributor for enSonix@home medical devices. LINEA COMMERCIAL will immediately commence the registration process with Brazil's ANVISA, Brazil's equivalent of the US Food and Drug Administration (FDA), and plans to take the initial delivery of product in the first quarter of 2007. The agreement is estimated to be worth a minimum of $9.0 Million to HealthSonix and will likely generate sales in excess of $10.0 Million in the first year when optional accessories for the device are included.

"The enSonix@home medical device has been given high marks for its efficacy by users of the product and the reasonable price point is considered an added bonus," stated Ivan X. deSouza, Chairman of the Board. "Brazil is the largest economy in South America and represents a very significant market for our products."

The agreement calls for a minimum of 100,000 enSonix@home units to be sold in the first year of the agreement. "Last week, the company announced the $4.5 Million sales commitment for 50,000 units by a Mexican distributor; with this additional $9 Million commitment from Brazil in place, we will be revising our sales forecasts upward for F'2007," added Dieter Doederlein, Vice President of Business Development.

HealthSonix recently registered and cleared the enSonix@home device with the United States Food and Drug Administration (FDA) and was designated as a class one device, the safest classification for medical devices. The product has been indicated for pain reduction and muscle relaxation.

About HealthSonix, Inc.

HealthSonix, Inc. (PINKSHEETS: HSXI) (FRANKFURT: H7S) is a publicly traded medical technology company. The Company's core offerings are based on proprietary, patent pending medical technologies that use sound pressure waves to administer sub-sensory micro vibration to the human body. Precisely formatted low frequency sound pressure waves are 80% effective in treating the pain of many diseases, particularly arthritis. All treatments and products are safe, non-invasive, drug free, and have no known side effects.

More information regarding HealthSonix and its products and services can be found at: www.HealthSonix.com or by calling the company at 1-877-622-2121.

Note: A number of statements contained in this report are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.

Contact Information